Co-expression of multiple gene products (proteins) within the same cell is critical for success in many areas of biomedicine and biotechnology. This can now be readily accomplished by using 2A co-expression technology, developed by the Ryan Laboratory.
This technology has been critical in strategies for:
- the use of human gene therapies targeting cancer
- the production of induced human pluripotent stem cells for regenerative medicine,
- the creation of transgenic animals and plants with improved nutritional properties and the production of high-value proteins for the pharmaceutical industry.
- Over 400 patent applications in the REF period utilise 2A, and multiple companies market products based on the technology.